{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:32Z","timestamp":1787026412633,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the clinical features and effects of octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease (ADPKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Databases were searched for randomized controlled trials (RCTs) evaluating octreotide long-acting release (LAR) in ADPKD from inception to December 2024. Two reviewers independently screened studies, extracted data, and assessed the risk of bias. Meta-analysis was performed using Stata 16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of six randomized controlled trials were included. Meta-analysis using a fixed-effects model showed no statistically significant difference in glomerular filtration rate (GFR) between the two groups [SMD = -0.020 (-0.250, 0.210), P = 0.864]. Meta-analysis using a random-effects model showed no statistically significant difference in total kidney volume (TKV) between the two groups [SMD= -0.001(-0.376,0.374), P = 0.996]. A fixed-effects model meta-analysis of a fixed effect model showed a statistically significant reduction in cystic kidney volume (CKV) between the two groups [RR = 1.127 (0.996, 1.276), P = 0.058]. Egger\u2019s test and funnel plot analysis indicated no publication bias for GFR, TKV, or CKV. Sensitivity analysis demonstrated that the study results were robust.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Octreotide long-acting release has a certain effect on reducing cystic kidney volume in patients with ADPKD but shows no significant effect on GFR or TKV and does not increase the risk of adverse reactions. These findings provide a certain reference for the clinical treatment of ADPKD; however, additional high-quality studies are still needed for further validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251242104.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1709818","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:36:16Z","timestamp":1769009776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengyan","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, West China Hospital of Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, People's Hospital of Nanjiang County","place":["Bazhong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital of Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"2025 Clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (Adpkd)","volume":"107","year":"2025","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.3390\/ijms25115646","article-title":"Cross-species insights into autosomal dominant polycystic kidney disease: provide an alternative view on research advancement","volume":"25","author":"Luo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.127","article-title":"New treatment paradigms for adpkd: moving towards precision medicine","volume":"13","author":"Lanktree","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.07.010","article-title":"Kdigo 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (Adpkd): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae159","article-title":"Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (Hrqol) in autosomal dominant polycystic kidney disease","volume":"17","author":"Rangan","year":"2024","journal-title":"Clin Kidney J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.3390\/nu15112621","article-title":"Diet and physical activity in adult dominant polycystic kidney disease: A review of the literature","volume":"15","author":"Capelli","year":"2023","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jama.2023.2161","article-title":"What is autosomal dominant polycystic kidney disease","volume":"329","author":"Alam","year":"2023","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2023.04.002","article-title":"The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M800068-MCP200","article-title":"A multiplexed quantitative strategy for membrane proteomics: opportunities for mining therapeutic targets for autosomal dominant polycystic kidney disease","volume":"7","author":"Han","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00057.2024","article-title":"Somatostatin peptides prevent increased human colonic epithelial permeability induced by hypoxia","volume":"327","author":"Rajput","year":"2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13643-022-01994-5","article-title":"Study protocol for developing, piloting and disseminating the prisma-cosmin guideline: A new reporting guideline for systematic reviews of outcome measurement instruments","volume":"11","author":"Elsman","year":"2022","journal-title":"Syst Rev"},{"key":"B14","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [Updated march 2011]","author":"Higgins","year":"2011"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000049","article-title":"Effects of octreotide\u2013long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial","volume":"18","author":"Trillini","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-lar in later-stage autosomal dominant polycystic kidney disease (Aladin 2): A randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PloS Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dialysis Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (Aladin): A randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00755.x","article-title":"Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease","volume":"63","author":"Nagao","year":"2003","journal-title":"Kidney Int"},{"key":"B22","first-page":"295","article-title":"Autosomal dominant polycystic kidney disease: clinical and genetic aspects","volume":"10","author":"Sessa","year":"1997","journal-title":"J Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020523","article-title":"Advances and challenges in modeling autosomal dominant polycystic kidney disease: A focus on kidney organoids","volume":"13","author":"Gu","year":"2025","journal-title":"Biomedicines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1053\/j.ajkd.2024.02.016","article-title":"Kidney energetics and cyst burden in autosomal dominant polycystic kidney disease: A pilot study","volume":"84","author":"Bjornstad","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-02145-w","article-title":"Octreotide-lar in adpkd patients with very low kidney function: A single-center real-life experience","volume":"37","author":"Riccio","year":"2024","journal-title":"J Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000529119","article-title":"Cardiovascular involvement in patients with autosomal dominant polycystic kidney disease: A review","volume":"49","author":"Pietrzak-Nowacka","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1311266","article-title":"Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin ii receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease","volume":"20","author":"Clark","year":"2017","journal-title":"J Med Econ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110773","article-title":"\u03b2-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease","volume":"27","author":"Torres","year":"2024","journal-title":"iScience"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.3c01397","article-title":"Investigation of basolateral targeting micelles for drug delivery applications in polycystic kidney disease","volume":"25","author":"Huang","year":"2024","journal-title":"Biomacromolecules"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12547","DOI":"10.3390\/ijms232012547","article-title":"Kidney cyst lining epithelial cells are resistant to low-dose cisplatin-induced DNA damage in a preclinical model of autosomal dominant polycystic kidney disease","volume":"23","author":"Saravanabavan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.3390\/ijms221910512","article-title":"Role of DNA-dependent protein kinase in mediating cyst growth in autosomal dominant polycystic kidney disease","volume":"22","author":"Chandra","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1709818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:41:41Z","timestamp":1771918901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1709818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":32,"alternative-id":["10.3389\/fendo.2025.1709818"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1709818","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1709818"}}